Previous 10 | Next 10 |
UTRECHT, The Netherlands and PHILADELPHIA, June 02, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the ...
UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the ...
UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ) (LAVA), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transfor...
LAVA Therapeutics press release (NASDAQ:LVTX): Q1 GAAP EPS of -$0.41 beats by $0.44. Revenue of $1M (+11.1% Y/Y) beats by $0.46M. As of March 31, 2022, LAVA had cash, cash equivalents and investments totaling $124.2M compared to cash and cash equivalents of $133.2M as of December 31, 202...
UTRECHT, The Netherlands and PHILADELPHIA, May 12, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the t...
UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of ca...
UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transfo...
LAVA Therapeutics (NASDAQ:LVTX) has filed for a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company said proceeds will be used for continued development of product candidates, and for general corporate purpo...
LAVA Therapeutics press release (NASDAQ:LVTX): Q4 GAAP EPS of -$0.38 misses by $0.01. Revenue of $1M (-50.0% Y/Y). As of December 31, 2021, cash, cash equivalents and investments totaling $133.2M For further details see: LAVA Therapeutics GAAP EPS of -$0.38 misses by $0.01, revenu...
LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022 LAVA-1207 Phase 1/2a trial in mCRPC on track to report initial data in H2 2022 New pipeline program: LAVA-1266, a CD123-d...
News, Short Squeeze, Breakout and More Instantly...
LAVA Therapeutics N.V. Company Name:
LVTX Stock Symbol:
NASDAQ Market:
LAVA Therapeutics N.V. Website:
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma delta T cell eng...
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamm...
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 LAVA-1266 on track for Q2 2024 IND sub...